Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.60    -0.05 (-0.40%)
Bid:
12.60
Ask:
12.95
Spread: 0.35 (2.778%)
Market Cap: £42.85m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

Trading Statement

6 Jun 2013 07:00

RNS Number : 4128G
BATM Advanced Communications Ld
06 June 2013
 



6 June 2013

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Trading Update

 

BATM Advanced Communications Limited (LSE: BVC; TASE: BATM), a leading provider of real-time technologies for the networked telecoms and medical laboratory equipment markets, provides the following update on trading.

 

As stated in the Group's interim management statement for the first quarter of 2013, BATM was on schedule to deliver solid growth in 2013. At the beginning of Q2 2013, the Group was gearing up its production in the Medical division businesses of diagnostics and pathogenic waste management in response to significant demand for its products. In order to meet this demand in the diagnostics business, BATM also increased spending on seeking registration. Disappointingly, components supplied by third parties failed to arrive during May as scheduled, and consequently BATM was unable to fulfill orders and was forced to postpone deliveries. However, the backlog remains substantial and, with certain components required to complete some orders having been received, the Group is working towards clearing this in the second half of 2013.

 

Separately, due to ongoing global economic and commercial uncertainty, the Group has re-enforced its policy of tight credit control for certain customers of the distribution business of the Medical division whereby shipping should only occur once payment has been received by BATM or it has complete confidence that payment will be forthcoming. Consequently, and in accordance with this policy, the Group was forced to stop supplies to certain major customers globally during May 2013. This has resulted in revenues in this business being lower than anticipated.

 

The consequence of the above factors is that the Group expects first half 2013 revenue and profit to be materially below management's expectations. In contrast, the Group has opened trading in June 2013 very well and its businesses are returning to normality. Accordingly, the Group expects H2 2013 performance to be in line with management's expectations. For the full year to 31 December 2013 as a whole, the Group still expects to achieve higher revenue and profit than for the full year to 31 December 2012.

 

Looking ahead, the fundamentals of the business remain strong. BATM's Telecom division's T-Metro 8000 platform and Edge Genie service management solution continue to attract interest from customers globally. The Group has also been asked to join consortia bidding for large, long-term contracts, and the Board is confident of being awarded contracts in thenear future. In the Medical division, the diagnostics business continues to grow and has a strong order book and backlog. In addition, the Group continues to increase the installations of its Integrated Sterilizer and Shredder systems in the sterilization business.

 

CELARE, the Group's subsidiary focusing on networks security, continues to perform well in its contract with the Israeli Defence Force. Due to the growing demand for products and services to protect networks against cyber-attacks, BATM has been in discussions with the relevant authorities to allow it to market part of its product line globally. BATM anticipates successful conclusion to these talks in 2013 and has accelerated its strategic plan for this business.

 

BATM will provide further details on trading for the first half of the year in its interim results announcement in August 2013.

Enquiries 

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Ofer Bar-Ner, Chief Financial Officer

finnCap

Stuart Andrews, Henrik Persson - Corporate Finance

+44 20 7220 0500

Brian Patient, Stephen Norcross - Corporate Broking

Shore Capital

Pascal Keane

+44 20 7408 4090 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVELFBXQFFBBD
Date   Source Headline
26th May 20267:00 amRNSBlock Listing Interim Review
21st Apr 20267:00 amRNSPublication of Annual Report
11th Mar 20267:00 amRNSFull Year Results
3rd Mar 202612:00 pmRNSHolding(s) in Company
10th Feb 20267:00 amRNSSale of Non-core Business
3rd Feb 20267:00 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RBATM selected as FPT Israel cybersecurity partner
12th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20267:00 amRNSHolding(s) in Company
8th Jan 202611:00 amRNSTransaction in own shares and Total Voting Rights
2nd Jan 20267:01 amRNSDirector Declaration
2nd Jan 20267:01 amRNSDirector Declaration
2nd Jan 20267:00 amRNSCompletion of Sale of Diagnostics Distributor
2nd Jan 20267:00 amRNSCompletion of Sale of Diagnostics Distributor
29th Dec 20257:00 amRNSAppointment of Chairman and Directorate Change
29th Dec 20257:00 amRNSAppointment of Chairman and Directorate Change
10th Dec 202512:00 pmRNSAGM Result, Directorate Change & AMS Sale Update
1st Dec 20257:00 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSBlock Listing Interim Review
17th Nov 20257:00 amRNSNew Carrier Ethernet Order
5th Nov 20257:00 amRNSNotice of AGM and Directorate Changes
6th Oct 20257:00 amRNSSale of Diagnostics Distributor
26th Sep 20257:00 amRNSDirectorate Change
18th Aug 20257:00 amRNSInterim Results
4th Aug 20257:00 amRNSTotal Voting Rights
24th Jul 20257:00 amRNSSale of Non-Core Businesses and Notice of Results
23rd Jun 20257:00 amRNSDirectorate Change
27th May 20257:00 amRNSBlock Listing Interim Review
12th May 20257:00 amRNSOrder for ultra-high speed encryption development
6th May 20257:00 amRNS-RBATM unveils new brand identity
8th Apr 202511:00 amRNSAnnual Report Publication and AGM Update Statement
27th Mar 20257:00 amRNSNew strategic customer for Edgility in Brazil
17th Mar 20257:00 amRNSFull Year Results
5th Mar 20257:00 amRNSUpdate on Strategy and Trading
24th Feb 20257:00 amRNSHolding(s) in Company
16th Jan 20257:00 amRNSADOR appoints Nadhim Zahawi to lead Advisory Board
19th Dec 20243:30 pmRNSResult of AGM and Director Appointment
19th Dec 20247:00 amRNSNew Tier 1 Customer for Edgility in Mexico
11th Dec 20247:00 amRNSNATlab commences pre-clinical validation
3rd Dec 20247:00 amRNSBlock Listing Interim Review
2nd Dec 20247:00 amRNSBATM receives orders of $2.4m for Edgility
25th Nov 20247:00 amRNSBlock listing Interim Review
14th Nov 202411:00 amRNSNotice of AGM and Proposed Director Appointment
4th Nov 20247:00 amRNSTotal Voting Rights
19th Aug 20247:00 amRNSInterim Results
10th Jul 20247:00 amRNSAmazon Web Services partnership for Edgility
2nd Jul 20247:00 amRNSCommercial markets cybersecurity partnership
3rd Jun 20247:00 amRNSBlock Listing Interim Review
28th May 20247:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.